IRB #

STUDY00017751

Title

Trans(Intra)-arterial Gemcitabine vs. Continuation of IV Gemcitabine and Nab-Paclitaxel following Radiotherapy for Locally Advanced Pancreatic Cancer

Principal Investigator

Charles Lopez

Study Purpose

To compare Gemcitabine given through the artery vs gemcitabine and nab paclitaxel given through the vein after receiving radiotherapy

Medical Condition(s)

"Locally Advanced Pancreatic Cancer” and “RenovoCath”

Eligibility Criteria

Histologically confirmed pancreatic adenocarcinoma with initial diagnosis

Age ≥ 18 years

No prior treatment for pancreatic cancer

Age Range

18 - 120

Healthy Volunteers Needed

No

Duration of Participation

Standard chemo and radiation for up to 17 weeks and IV or arterial doses until disease progression with up to 3 years of follow-up.

Minors Included

No

Contact

Knight Clinical Trials Information Line
503-494-1080

Sponsor

RenovoRx, Inc

Recruitment End

11/30/2027

Compensation Provided

No


Go Back